| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Sep, 2023 | Jun, 2023 |
| Sales | 500 | 390 | 520 | 750 | 790 |
| Sales Growth | +28.21% | -25.00% | -30.67% | -5.06% | +1.28% |
| Net Income | -400 | -650 | -390 | -820 | -400 |
| Net Income Growth | +38.46% | -66.67% | +52.44% | -105.00% | +77.90% |
Stagezero Life Sciences Ltd (SZLSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
StageZero Life Sciences Ltd is dedicated to the early detection of cancer and multiple disease states through whole blood. The company's test consists of Aristotle(R), a multi-cancer panel for simultaneously screening for cancers from a single sample of blood. StageZero Life Sciences Ltd, formerly known as GeneNews Ltd., is based in TORONTO, ON.
Fiscal Year End Date: 12/31